Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets | News Direct
Teva down as it reports lower sales and profit for 2018
Teva concludes $703m women's health products deal with CVC Capital - Pharmaceutical Technology
Global Fluconazole Market 2018 - Pfizer, Bayer, Teva
FDA approves a generic version of Teva Pharmaceutical's best-selling drug; company shares tumble
Israel's Teva gives upbeat outlook as restructuring proceeds
Teva Pharm to lay off a quarter of workforce, suspends dividend | Reuters
Teva Execs Topped TASE's High Earners List for 2018 | Ctech
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
Patients Eagerly Awaited a Generic Drug. Then They Saw the Price. - The New York Times
Teva Reports Fourth Quarter and Full Year 2019 Financial Results | Business Wire
Teva Announces New Brand Positioning and Visual Identity in North America
Teva Pharmaceutical falls 6% on eve of Q3 earnings show | Seeking Alpha
Teva Selling $3.5 Billion of Junk Bonds to Refinance Debt - Bloomberg
Teva Pharmaceuticals: Israeli drugmaker to cut 14,000 jobs - BBC News
15. Teva Pharmaceutical Industries | FiercePharma
What's behind the timed resurgence of lawsuits against Teva? | Ctech
Teva Stock Dives As The Sales Downfall Continues For Its Biggest Product | Investor's Business Daily
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ANJL4AXVTBOMDKS2X4DIJZXZAY.jpg "Teva loses bid to cancel Corcept drug patent at Federal Circuit | Reuters")
Teva loses bid to cancel Corcept drug patent at Federal Circuit | Reuters
Jury holds drugmaker Teva liable in opioid crisis | KGAN
Teva Wins Three, Loses Six in Patent Battle Over Migraine Drug | BioSpace
Teva earnings Q2 2018 | AlphaStreet
Teva Pharmaceuticals soars after Warren Buffett's Berkshire Hathaway discloses a stake (TEVA) | Markets Insider
Why Teva Pharmaceuticals Stock Has Two A-Products In The Bag (NYSE:TEVA) | Seeking Alpha
18. Teva Pharmaceutical Industries | FiercePharma
Teva Pharmaceutical | P3 Properties | NJ Office Market
Teva reports massive $11.6 billion loss, predicts weak 2018 - Business - Haaretz.com
